Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CAR T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

XMXi MingXZXiaojian Zhu

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates CAR T-cell therapy improves complete response in patients with refractory breast lymphoma, indicating efficacy in hematological malignancies.

Key Points

  • Complete responses were observed in seven out of 11 patients treated with CAR T-cell therapy, demonstrating its potential efficacy.
  • Clinical outcomes revealed an overall response rate of 72.73% in this cohort, highlighting treatment success.
  • The assessment involved comparing CAR T-cell therapy alone and in combination with autologous stem cell transplantation in 11 adult patients.
  • This therapy had manageable toxicity profiles, with no serious cytokine release syndrome events reported among patients.

Cite This Study

Ming et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8f7https://doi.org/10.1182/blood-2025-7245
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma2025
  2. 2CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations
  3. 3Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma2025
  4. 4Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis2025 · 1 citations
  5. 5Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2025